Marvel Biosciences Corp. (MRVL.V)

CAD 0.16

(10.34%)

Operating Expenses Summary of Marvel Biosciences Corp.

  • Marvel Biosciences Corp.'s latest annual operating expenses in 2023 was 2.31 Million CAD , up 16.19% from previous year.
  • Marvel Biosciences Corp.'s latest quarterly operating expenses in 2024 Q3 was 237.74 Thousand CAD , up 14.03% from previous quarter.
  • Marvel Biosciences Corp. reported a annual operating expenses of 1.17 Million CAD in annual operating expenses 2022, up 141.45% from previous year.
  • Marvel Biosciences Corp. reported a annual operating expenses of 485.04 Thousand CAD in annual operating expenses 2021, down -29.66% from previous year.
  • Marvel Biosciences Corp. reported a quarterly operating expenses of 208.48 Thousand CAD for 2024 Q2, down -8.59% from previous quarter.
  • Marvel Biosciences Corp. reported a quarterly operating expenses of 228.07 Thousand CAD for 2024 Q1, down -45.36% from previous quarter.

Annual Operating Expenses Chart of Marvel Biosciences Corp. (2023 - 2019)

Historical Annual Operating Expenses of Marvel Biosciences Corp. (2023 - 2019)

Year Operating Expenses Operating Expenses Growth
2023 2.31 Million CAD 16.19%
2022 1.17 Million CAD 141.45%
2021 485.04 Thousand CAD -29.66%
2020 689.57 Thousand CAD 589.23%
2019 100.04 Thousand CAD 0.0%

Peer Operating Expenses Comparison of Marvel Biosciences Corp.

Name Operating Expenses Operating Expenses Difference
Arch Biopartners Inc. 3.22 Million CAD 28.121%
Covalon Technologies Ltd. 14.36 Million CAD 83.854%
Hemostemix Inc. 2.15 Million CAD -7.52%
Universal Ibogaine Inc. 5.81 Million CAD 60.136%
Kane Biotech Inc. 3.46 Million CAD 33.111%
MedMira Inc. 1.5 Million CAD -53.632%
NervGen Pharma Corp. 17.77 Million CAD 86.955%
XORTX Therapeutics Inc. 6.38 Million CAD 63.664%